About Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
ABOS Key Statistics
| Current Price | $3.37 | Market Cap | $200 million |
|---|---|---|---|
| Daily Change | +1.81% | Volume | 211K |
| 52-Week High | $3.41 | 52-Week Low | $0.86 |
| Sector | Healthcare | Industry | Biotechnology |
ABOS Price Performance
Acumen Pharmaceuticals, Inc. stock has returned -0.90% over the past day, +5.41% over the past week, +31.87% over the past month, and +84.92% over the past three months. The stock trades between a 52-week low of $0.86 and a high of $3.41.
ABOS Financial Fundamentals
Acumen Pharmaceuticals, Inc. reports a return on equity (ROE) of -85.93%. The debt-to-equity ratio is 0.33. Current ratio stands at 6.02.